Knock-on effects of early immune checkpoint inhibitor use stimulate consideration of alternative approaches for further treatment lines  

Phase III data highlight the consistent benefit of anti-PD-1 therapy for oesophageal and gastric cancer patients, with greatest benefit in high PD-L1-expressing tumours

Trials provide insights into perioperative and adjuvant chemotherapy for resectable pancreatic cancer

Good response rate and disease control with adagrasib and sotorasib in combination therapy shown in early-stage trials

Immune chemo-sensitisation results show potential for this approach in the treatment of advanced CRC, but greater understanding of response characteristics is required in future clinical trials

Genomic landscaping suggests molecular divergence between cancer subtypes and across disease stages, but molecular similarities between White and Asian populations

Triplet targeted combination therapy appears to induce potent BRAF kinase signalling inhibition in patients with BRAFV600E-mutated metastatic colorectal cancer

Targeting isocitrate dehydrogenase 1 mutations in cholangiocarcinoma is a promising strategy

Mixed results from the the HERACLES-B, TRIUMPH and MOUNTAINEER trials

At ESMO 2019, early clinical data from two studies show the promise of this new generation of treatments although not yet practice-changing